Regeneron (REGN) Tops Q2 EPS by $1.18, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Regeneron Reports Second Quarter 2020 Financial and Operating Results
August 5, 2020 6:30 AM EDTTARRYTOWN, N.Y., Aug. 5, 2020 /PRNewswire/ --Â
Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4) Second quarter 2020 EYLEA® U.S. net sales were $1.11 billion Second quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, were $945 million Second quarter 2020 GAAP diluted EPS was $7.61 and non-GAAP diluted EPS(1) was $7.16 Initiated Phase 2 and Phase 3 clinical trials of REGN-COV2 for the treatment and prevention of COVID-19 FDA approved Dupixent for children aged 6 to 11 years with moderate-to-severe atopic dermatitis Dupixent eosinophilic... More